GRFS
Grifols SA - ADR - Level III
$8.44
Earnings Summary
PE Ratio | 88.7 |
Highlights
Grifols SA - ADR - Level III’s price-to-earnings ratio after this Q2 2022 earnings stands at 88.7.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Grifols SA - ADR - Level III post its latest quarter earnings
EPS Estimate Current Year | 0.23 |
Highlights
Grifols SA - ADR - Level III’s earning per share (EPS) estimates for the current year stand at 0.23.
Key Ratios
Key ratios of the Grifols SA - ADR - Level III post its Q2 2022 earnings
Earning Per Share (EPS) | 0.14 |
Return on Assets (ROA) | 0.02 |
Return on Equity (ROE) | 0.02 |
Dividend Per Share (DPS) | 0 |
Highlights
Grifols SA - ADR - Level III’s earning per share (EPS) fell -41% since last year same period to 0.14 in the Q2 2022. This indicates that the Grifols SA - ADR - Level III has generated -41% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Grifols SA - ADR - Level III’s return on assets (ROA) stands at 0.02.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Grifols SA - ADR - Level III’s return on equity (ROE) stands at 0.02.
Grifols SA - ADR - Level III declared 0 dividend per share during the earnings announcement for Q2 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2021-06-30 | 0.23 | 0.24 | 4.35% |
Company Information
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 100 countries. Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. In 2019, Grifols' economic impact in its core countries of operation was EUR 8.5 billion. The company also generated 148,000 jobs, including indirect and induced.
Organisation | Grifols SA - ADR - Level III |
Headquarters | Barcelona, Barcelona, Spain |
Employees | 2.02K |
Industry | Health Technology |